ClinicalTrials.gg
RecruitingNCT05997602Updated Jan 24, 2025

To Evaluate the Efficacy, Safety, and PK Characteristics of FCN-159 in Pediatric Patients With Refractory/Recurrent LCH

A Phase 2 interventional study of FCN-159 in Langerhans Cell Histiocytosis and LCH, sponsored by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.. Recruiting at 11 sites in China. Open to participants aged 2 Years to 16 Years. Per ClinicalTrials.gov, last updated 2025-01-24.

Sponsored by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (part of Fosun Pharma) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 6 months ago, but the record still lists the study as recruiting.
  • Started Sep 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
56
Allocation
Not applicable
Ages
2 Years to 16 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies in Histiocytosis, Langerhans-Cell with a site in China — 11 open to participants now, 13 under way, 1 of them phase 3. Histiocytosis, Langerhans-Cell · China.

Planned enrollment
5th of 17
56 · median 40
Started
2023
with 1 other
Phase 2
10 of 17
5 open now
Primary completion
2025-05
later than 2 of 12 live
Registered
8th of 17
by date
Lead sponsor
1 of 17
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

Among the 17 studies in Histiocytosis, Langerhans-Cell with a site in China, this one is the 5th largest by planned enrollment, is one of 2 that started in 2023, is one of 10 in phase 2, reaches primary completion later than 2 of the 12 other live ones, and was the 8th registered.

Histiocytosis, Langerhans-Cell

81 studies on the registry are indexed under Histiocytosis, Langerhans-Cell; 23 are open to participants now.

Browse Histiocytosis, Langerhans-Cell studies →

Open to participants now

11 of the 17 studies in Histiocytosis, Langerhans-Cell with a site in China are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 19 Histiocytosis, Langerhans-Cell studies recruiting now, 8 (42%) set no upper age limit and 10 (53%) stop at 75 or younger; 13 take children under 18; 1 takes healthy volunteers.

This study: 2 Years to 16 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Histiocytosis, Langerhans-Cell with a site in China, or all of them as a file.
02

Study summary

This is a rare disease, single-arm, open-label,multi-center, non-randomized Phase 2 clinical study to evaluate the efficacy, safety, and pharmacokinetic characteristics of FCN-159 monotherapy in pediatric patients with refractory/recurrent Langerhans cell histiocytosis (LCH).

Read the detailed description

This is a rare disease, single-arm, open-label,multi-center, non-randomized Phase 2 clinical study to evaluate the efficacy, safety, and pharmacokinetic characteristics of FCN-159 monotherapy in pediatric patients with refractory/recurrent Langerhans cell histiocytosis (LCH). Approximately 56 pediatric patients will be enrolled in this study.The study included screening period, treatment period and follow-up period. Subjects will receive FCN-159 5mg/m² (NMT 8mg, the recommended oral dose for adults), orally, once daily, continuously for 28 days per cycle. Subjects will be treated until disease progression (PD), intolerable toxicity, withdrawal of consent, death, or other protocol-specified reasons. According to the PET Response Criteria and Langerhans Cell Histiocytosis Evaluation and Treatment Guidelines, tumor assessment will be performed until disease progression, death, and withdrawal of information Intention, loss of follow-up, initiation of new antitumor therapy, or study termination.Efficacy evaluation will be performed by the investigator and the Independent Review Committee (IRC), respectively.

03

Conditions studied

  • Langerhans Cell Histiocytosis
  • LCH
04

Who can participate

Ages eligible
2 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 2-16 (inclusive)
  2. Patients with confirmed Langerhans cell histiocytosis (LCH) diagnosed by the central laboratory.
  3. If sufficient tumor tissue samples and peripheral blood samples are available, central laboratory biomarker testing is required as follows: including but not limited to ERBB3, BRAF, ARAF, HRAS, KRAS, NRAS, MEK (MAP2K1 and MAP2K2), and other MEK upstream genes.If inability to get tissue, the gene testing results from a local laboratory also can be accepted.
  4. Patients who have received at least prior systemic treatment, defined as treatment including vinblastine (VBL) and for at least 2 weeks. VBL can be substituted with vincristine (VCR) or vindesine (VDS). Alternatively, patients may be unable to tolerate chemotherapy due to severe chemotherapy toxicity. Inability to tolerate chemotherapy is defined as one of the following: Severe liver impairment (liver enzyme elevation ≥ 5 × (ULN) and elevation ≥ 1.5 × ULN), severe neurotoxicity related to vinca alkaloids, chemotherapy-related intracranial hypertension, or grade 4 bone marrow depression with severe infection (sepsis, severe pneumonia, etc.) after chemotherapy.
  5. /relapsed LCH is defined as the presence of one of the following:

    1. Failure of prior treatment, i.e., no regression in risk organs after at least 2 weeks of systemic treatment, or overall evaluation of AD-progression or AD-mix;
    2. Initial response of the disease to first or second-line systemic treatment is NAD or AD-better or AD-stable, followed by disease reactivation after maintenance therapy for more than 3 months. Second-line treatment includes cytarabine and/or cladribine.
    3. Persistent mutated gene positive in plasma free DNA testing during prior treatment (confirmed by 2 consecutive tests) or retest positive after treatment discontinuation;
    4. Lack of regression in the affected central nervous system (including the pituitary gland) after treatment;
    5. Presence of bone marrow involvement and/or hemophagocytic lymphohistiocytosis (HLH);
  6. Presence of evaluable lesions based on PET response criteria (PRC).
  7. Patients who have to have recovered from all acute toxic effects of prior anti-tumor therapy, and all relevant toxicities must be ≤ grade 1 (except for alopecia and ototoxicity).
  8. Expected survival at least ≥ 3 months;
  9. Lansky (≤ 15 years old) and (≥ 16 years old) performance status scores should be ≥ 50%, as shown in Appendix 4.
  10. Patients or their legal guardians must be able to understand and willingly sign a written form.
  11. For women of , a serum human chorionic gonadotropin (HCG) pregnancy test must be negative within 7 days before starting treatment.
  12. For female patients of childbearing potential: Patients should agree to use effective methods during the treatment period and for at least 90 days after the last dose of study treatment, using dual barrier contraception methods such as condoms, oral or injectable contraceptives, intra-uterine contraceptive devices, etc. Male patients should agree to refrain from donating sperm for at least 90 days after the last dose of study treatment.
  13. Adequate bone marrow function: ≥ 1.0×10\^9/L, ≥ 90g/L, and ≥ 75×10\^9/L without the use of blood transfusions, blood products, or granulocyte colony-stimulating factors. Patients with hematocytopenia below these thresholds due to the underlying disease may be considered for inclusion based on the investigator's comprehensive judgment.
  14. Adequate hepatic and renal function: Serum total bilirubin ≤ 1.5 × the upper limit of normal (ULN), or ≤ 5× ULN for patients with Gilbert's syndrome or liver involvement; (AST), alanine aminotransferase (ALT), and alkaline phosphatase (AKP) ≤ 2.5 × ULN, or ≤ 10 × ULN for patients with liver involvement; albumin ≥ 3g/dL; and or isotopic (GFR) ≥ 50ml/min/1.73㎡or serum creatinine based on age; hepatic and renal impairment caused by the primary disease may be considered for inclusion based on the investigator's comprehensive judgment.
  15. Coagulation: (INR) and activated partial thromboplastin time (APTT) ≤ 1.5 ULN.

Exclusion criteria

Exclusion Criteria:

  1. Patients who have received any of the following prior treatments:

    1. Chemotherapy, targeted therapy, immunotherapy, biologic therapy, or herbal anti-tumor therapy for LCH within 4 weeks or \< 5 half-lives (whichever is shorter)before the start of the study drug .
    2. Strong , CYP2C8, and CYP2C9 inhibitors or inducers within 14 days before the start of the study drug, except for topical skin application.
    3. Gowth factors that promote or white blood cell count or function within 7 days before the start of the study drug.
    4. Radiotherapy or major surgical treatment (including craniotomy, thoracotomy, laparotomy, open bone or joint surgery, etc.) within 4 weeks before the start of the study drug.
    5. Participated in other interventional clinical trials within 4 weeks before the start of the study drug.
    6. MEK 1/2 inhibitors (those who have received this treatment for a short period of ≤ 2 weeks may be included).
    7. Anticoagulants within 7 days before the start of the study drug for patients with brain tumors (intracranial masses).
    8. Prednisone treatment \< 0.5mg/kg/day (or equivalent dose of other ) is allowed within one month before enrollment, but must be discontinued 14 days before the start of the study drug. Patients with brain lesions receiving corticosteroid therapy for brain edema must maintain a stable dose for 14 days before enrollment. Hormone replacement therapy is allowed for patients with hypopituitarism due to primary disease involvement of the pituitary.
  2. Patients with a history of other malignant tumors or concurrent other malignant tumors (excluding cured non-melanoma skin basal cell carcinoma, ductal carcinoma in situ of the breast, or cervical carcinoma in situ).
  3. Uncontrolled hypertension (with medication treatment): Blood pressure (BP) greater than or equal to the 95th percentile for age, height, and sex, as described in Appendix 6.
  4. Patients with dysphagia, active gastrointestinal disease, malabsorption syndrome, or other conditions that may affect the absorption of the study drug.
  5. Prior or current history of retinal vein obstruction (RVO), retinal pigment epithelial detachment (RPED), glaucoma, and other abnormal ophthalmologic examination results.
  6. Interstitial pneumonia, including clinically significant radiation pneumonitis. Except for interstitial pneumonia caused by pulmonary involvement of the primary disease.
  7. Patients will be excluded if their cardiac function or comorbidities meet any of the following criteria:

    1. During the screening period, 12-lead (ECG) measurements will be taken three times at the study center with a mean value calculated using the formula provided by the instrument; patients with a mean value of QTcF > 470 milliseconds or with risk factors for QTcF prolongation, such as uncorrected hypokalemia, congenital long QT syndrome, or receiving drugs known to prolong QTcF interval (mainly class Ia, Ic, and III antiarrhythmic drugs) will be excluded from the study. Drugs with the potential to prolong the QTcF interval are listed in Appendix 7.
    2. (NYHA) Class 2 and above congestive heart failure as shown in Appendix 5.
    3. Clinically significant arrhythmias, including but not limited to complete left bundle branch block, and second-degree atrioventricular block.
    4. Known presence of clinically significant coronary heart disease, cardiomyopathy, or severe valvular disease.
    5. Echocardiography examination indicating (LVEF) \< 50%.
  8. Patients with active bacterial, fungal, or viral infections, including active (defined as positive hepatitis B surface antigen and hepatitis B virus DNA > 1000IU/ml or meeting the diagnostic criteria for active hepatitis B infection at the study center) or (positive hepatitis C virus RNA), or (HIV positive) infection.
  9. Patients with known allergies to the study drug, other MEK1/2 inhibitors, or their .
  10. Patients with known tumor tissue genetic testing that indicates the presence of MAP2K1 exon 3 deletions (del) or deletion-insertion type (delins/indels) mutations.
  11. The investigator considers clinically significant cases that will impede participation in the study or prevent compliance with safety requirements.
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
56 participants (estimated)

Study arms

  • Experimental
    FCN-159

    Experimental: FCN-159 Dosage form:tablet Specification: 1mg,4mg Dose: FCN-159 5mg/m² (Maximum dose does not exceed 8mg), orally, once daily

    Drug: FCN-159

Interventions

  • 5mg/m² (Maximum dose does not exceed 8mg, the recommended oral dose for adults), orally, once daily, continuously for 28 days per cycle.

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) Evaluated by Independent Review Committee (IRC) Based on PET Response Criteria (PRC)

    ORR Evaluated by Independent Review Committee (IRC) Based on PET Response Criteria (PRC) is defined as the percentage of participants who achieved a best overall response of CMR or PMR assessed by IRC .

    Time frame: up to 24months

Secondary outcomes

  1. Objective Response Rate (ORR) Evaluated by Investigator Based on PET Response Criteria (PRC) and Langerhans Cell Histiocytosis Evaluation and Treatment Guidelines (Histiocyte Society, April 2009, hereinafter referred to as "Guidelines")

    The ORR Evaluated by Investigator Based on PRC is defined as the percentage of participants who achieved a best overall response of CMR or PMR assessed by investigator. The ORR Evaluated by Investigator Based on "Guidelines" is defined as the percentage of participants who achieved confirmed NAD or AD-better assessed by investigator.

    Time frame: up to 24months

  2. Disease Control Rate (DCR) Evaluated by Investigator Based on PET Response Criteria (PRC) and "Guidelines".

    The DCR Evaluated by Investigator based on PRC is defined as the percentage of participants who achieved a best overall response of CMR or PMR or SMD assessed by investigator. The DCR Evaluated by Investigator Based on "Guidelines" is defined as the percentage of participants who achieved a confirmed NAD or AD-better or AD-stable assessed by investigator.

    Time frame: up to 24months

  3. Clinical benefit rate (CBR) Evaluated by Investigator Based on PRC and "Guidelines".

    The CBR Evaluated by Investigator based on PRC is defined as the percentage of participants who achieved a best overall response of CMR or PMR or SMD for a duration of ≥ 24 weeks assessed by investigator. The CBR Evaluated by Investigator Based on "Guidelines" is defined as the percentage of participants who achieved confirmed NAD or AD-better or AD stable for a duration of ≥ 24 weeks assessed by investigator.

    Time frame: up to 24months

  4. Time to Response (TTR) Evaluated by Investigator Based on PET Response Criteria (PRC) and "Guidelines"

    The TTR Evaluated by Investigator based on PRC is defined as the time from the first documented achievement of CMR or PMR (whichever comes first) assessed by investigator. The TTR Evaluated by Investigator based on the "Guidelines" criteria is defined as the time from the first documented achievement of NAD or AD-better (whichever comes first) assessed by investigator.

    Time frame: up to 24months

  5. One-year Progressive Free Survival (PFS) Rate Evaluated by Investigator Based on PET Response Criteria (PRC) and "Guidelines"

    The 1-year PFS Rate Evaluated by Investigator based on PRC is defined as the percentage of participants who did not achieve the first documented occurrence of PMD or death (whichever comes first) within one year after first administration of the study drug assessed by investigator. The 1-year PFS Rate Evaluated by Investigator based on "Guidelines" is defined as the percentage of participants who did not achieve the first documented occurrence of AD-progression or death (whichever comes first) within one year after first administration of the study drug assessed by investigator.

    Time frame: up to 12months

  6. Progressive Free Survival (PFS) Evaluated by Investigator Based on PET Response Criteria (PRC) and "Guidelines"

    The PFS Evaluated by Investigator based on PRC is defined as the time from the first administration of the study drug to the first documented occurrence of PMD or death (whichever comes first) assessed by investigator. The PFS Evaluated by Investigator based on "Guidelines" is defined as the time from the first administration of the study drug to the first documented occurrence of AD-progression or death (whichever comes first) assessed by investigator.

    Time frame: up to 24months

  7. Overall Survival (OS)

    The OS is defined as the time from the first administration of the study drug in patients to death from any cause. Data from the patient without events will be censored at the date the patient is last known to be alive

    Time frame: up to 24months

  8. One-year Overall Survival (OS) Rate

    The 1year OS Rate is defined as as the percentage of participants who did not achieve death due to any cause within one year after first administration of the study drug.

    Time frame: up to 12months

  9. Two-year Progressive Free Survival (PFS) rate Evaluated by the PRC and "Guidelines"

    The 2-year PFS Rate Evaluated by Investigator based on PRC is defined as the percentage of participants who did not achieve the first documented occurrence of PMD or death (whichever comes first) within two year after first administration of the study drug. The 2-year PFS Rate Evaluated by Investigator based on "Guidelines" is defined as the percentage of participants who did not achieve the first documented occurrence of AD-progression or death (whichever comes first) within two year after first administration of the study drug.

    Time frame: up to 24months

  10. Two-year Overall Survival (OS) Rate

    The 2 year OS Rate is defined as the percentage of participants who did not achieve death due to any cause within two year after first administration of the study drug.

    Time frame: up to 24months

  11. Treatment-emergent adverse events (TEAEs)

    Type and frequency of treatment-emergent adverse events (TEAEs) with toxicity grades evaluated according to the National Cancer Institute-Common Toxicity Criteria Adverse Event (NCI-CTCAE) version 5.0.

    Time frame: up to 24months

  12. Plasma Concentration of FCN-159

    Evaluation of the pharmacokinetic characteristics of FCN-159

    Time frame: up to 24months

07

Study locations

2 of 11 sites recruiting
  • Beijing Children's Hospital, Capital Medical University
    Beijing, Beijing, China
    Recruiting
    • Rui Zhang · Contact
    • Rui Zhang, MD · Principal investigator
  • Children's Hospital Affiliated to the Capital Institute of Pediatrics
    Beijing, Beijing, China
    Not yet recruiting
  • Children's Hospital of Chongqing Medical University
    Chongqing, Chongqing, China
    Recruiting
    • Jie Yu · Contact1808106657@qq.com · 13983762652
    • Jie Yu, MD · Principal investigator
  • Sun Yat-Sen Memorial Hpsipital,Sun Yat-Sen Unniversity
    Guangzhou, Guangdong, China
    Not yet recruiting
    • Jianpei Fang, MD · Contact
    • Jianpei Fang, MD · Principal investigator
  • The First Affiliated Hospital,Sun Yat-sen University
    Guangzhou, Guangdong, China
    Not yet recruiting
    • Xuequn Luo · ContactL-xuequn@126.com · 18902233573
    • Xuequn Luo, MD · Principal investigator
  • Shenzhen Children's Hospital
    Shenzhen, Guangdong, China
    Not yet recruiting
    • Sixi Liu, MD · Contacttiger647@126.com · 18938690206
    • Sixi Liu, MD · Principal investigator
  • Henan Children's Hospital Zhengzhou Children's Hospital
    Zhengzhou, Henan, China
    Not yet recruiting
  • Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology
    Wuhan, Hubei, China
    Not yet recruiting
    • Aiguo Liu · Contactdrliuaiguo@163.com · 13807196944
    • Aiguo Liu, MD · Principal investigator
  • West China Second University Hospital,Sihuan University/West China women's and Children's Hospital
    Chengdu, Sichuan, China
    Not yet recruiting
    • Ju Gao, MD · Contactgaoju651220@126.com · 18180609278
    • Ju Gao, MD · Principal investigator
  • Children's Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang, China
    Not yet recruiting
    • yongmin Tang · Contacty_m_tang@zju.edu.cn · 13858024301
    • yongmin Tang, MD · Principal investigator
  • Children's Hospital of Soochow University
    Suzhou, China
    Not yet recruiting
    • Shaoyan Hu · Contacthsy139@126.com · 13771870462
    • Shaoyan Hu, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for May 2025, 19 months after the start.

Of 32 phase 2 interventional studies under Histiocytosis, Langerhans-Cell, half reached primary completion within 63 months of starting (the median), counting those still running; a quarter within 55 and three quarters within 85. This study's planned 19 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2023
First posted
Aug 18, 2023
StartActual
Sep 28, 2023
Primary completionEst.
May 14, 2025
CompletionEst.
May 14, 2027
Last update
Jan 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05997602
Responsible party
Sponsor
First posted
Aug 18, 2023
Start date
Sep 28, 2023
Primary completion
May 14, 2025 (estimated)
Completion
May 14, 2027 (estimated)
Last update
Jan 24, 2025

Study contacts

Rui Zhang, MD
Contact
ruizh1973@126.com
18611106187
Rui Zhang, MD
principal investigator · Beijing Children's Hospital,Captial Medical University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Luvometinib

Start the discussion